普莱柯：子公司获得新兽药注册证书

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, which will enhance its product offerings in the poultry vaccine market [1] Group 1: Product Development - The new veterinary drug is a trivalent inactivated vaccine for preventing Newcastle disease, H9 subtype avian influenza, and infectious bursal disease [1] - The vaccine is characterized by efficient production, high expression, and long-lasting immunity [1] Group 2: Market Impact - The approval of the new veterinary drug certificate will enrich the company's poultry vaccine product line and improve its competitive edge in the market [1]